Dr Bec is a much more qualified CAR-T expert then IMU's LC, that way she should have a bit more credibility. But when it comes to " .... can't wait to present results ..." then yes, it sounds too familiar.
Anyway, let's assume 2025 would be the breakthrough for NK, what does it do to the sp? First, sp goes to 1c but then the nightmare starts. About 500-650m 0.8c oppies could be converted. That is most likely done by selling heads for 0.9c / 1c and then, if those could be absorbed by new buyers, one can expect at least half of those converted will be placed for sale again at 0.9c / 1c. That is the usual way and would mean up to 1b shares need to be turned over before any further rise. That way, holders would need to be patient. Of course, that number could be a lot less if Hopper doesn't do it and pays cash or, by selling IMU shares- LOL, and / or someone big gets interested.
Anything is possible, both ways. Over time the sp could climb if data are extraordinarily good. And that is the unknown, what will big pharma and big investor value as extraordinary. CD19 CAR-Ts have a huge success bar to overcome, CDH17's height is lower as there is no comparison at this stage. Dr Bec's pharma friends will be the first indication. If they put a few USD into CHM then it is a good indication, if they don't, all is over for CHM.
As a fence sitter there is no rush atm as the oppie scenario will keep the sp close to 1c for a while in case there are stunning results. And if not, then there won't be any reason to ever buy again.
GLTA
CHM Price at posting:
0.7¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)